S. Thungappa

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

M. Kudo, P. Galle, J. Furuse, 2022, NEJM evidence.

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

M. Kudo, J. Furuse, G. Abou-Alfa, 2022, Journal of Clinical Oncology.

Safety and Efficacy of Neoadjuvant DOF [Docetaxel, Oxaliplatin, 5-Fluorouracil] Chemotherapy Regimen in Patients with Locally Advanced Gastric and Gastro-Esophageal Junction Cancers: A Single Center Experience from India

Rajesh Kumar, V. Kulkarni, S. Patil, 2020, Journal of Cancer Therapy.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Landscape of clinically actionable mutations in breast cancer ‘A cohort study’

G. Srinivasachar, P. Agrawal, Ashwini Manjunath, 2020, Translational oncology.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

T. Crocenzi, Tae-You Kim, Y. Hotko, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.